Strengthening its structural heart pipeline, Boston Scientific expands into next-generation transcatheter aortic valve technology with an optional full acquisition pathway. Boston Scientific has agreed to invest $1.5bn to acquire a 34% equity stake in MiRus, gaining exposure to its SIEGEL Balloon Expandable transcatheter aortic valve replacement (TAVR) system, with an option to acquire full ownership of the TAVR business for up to an additional $3bn contingent on clinical and regulatory milestones. The deal reinforces Boston Scientific’s strategy of expanding its structural heart franchise through differentiated valve technologies, while securing an option-driven pathway to fully integrate a next-generation TAVR platform into its cardiovascular portfolio. A Strategic Entry Into Next-Generation TAVR Technology At the centre of the transaction is MiRus’ SIEGEL TAVR system, a balloon-expandable valve featuring a rhenium alloy frame designed to eliminate nickel exposure and improve biocompatibility in patients with severe aortic stenosis. The valve uses dry porcine tissue leaflets combined with a nitric oxide-coated rhenium frame engineered for high radial strength, with an open-cell design intended to support precise placement and reduce foreshortening during deployment. The system is delivered via an 8-Fr expandable sheath, approximately 50% smaller than many current commercial TAVR delivery systems, with the potential to reduce vascular complications and improve procedural access in higher-risk patient populations. Expanding Clinical Development and Platform Optionality MiRus has initiated the STAR pivotal trial evaluating the SIEGEL valve across multiple sizes in up to 1,025 patients with severe, symptomatic aortic stenosis across a range of surgical risk profiles. Boston Scientific’s agreement includes milestone-based optionality to acquire full control of the TAVR business, as well as additional potential payments tied to regulatory progress and net sales performance, alongside an exclusive option to acquire MiRus mitral and tricuspid valve technologies. This structure provides Boston Scientific with staged exposure to both clinical validation and commercial scalability before committing to full acquisition. Why This Deal Matters Now The investment reflects increasing competition in structural heart innovation, particularly in TAVR systems where device miniaturisation, deliverability, and long-term durability are becoming key differentiators. As the prevalence of aortic stenosis continues to rise, device manufacturers are competing to expand procedural access through lower-profile delivery systems and improved haemodynamic performance, while also addressing biocompatibility concerns associated with existing materials. MiRus’ rhenium-based architecture and reduced sheath size position the platform as a potential next-generation entrant in a mature but rapidly evolving TAVR market. What This Means for the Industry This transaction highlights three broader trends in medtech and structural heart investment: Companies are increasingly using minority stakes to secure early access to differentiated platforms Option-based acquisition structures are becoming a preferred de-risking mechanism in capital-intensive device development Innovation focus is shifting toward access, deliverability, and material science in structural heart systems At the same time, competition in TAVR remains intense, with established players continuing to iterate on device profiles, valve durability, and procedural outcomes. Boston Scientific’s investment signals a continued push to build depth in structural heart therapies ahead of future market expansion and competitive consolidation. Summary Boston Scientific’s $1.5bn investment in MiRus strengthens its position in structural heart innovation while securing optional full ownership of a next-generation TAVR platform. The deal reflects a broader industry shift toward staged acquisitions and differentiated device architectures aimed at improving procedural safety, access, and long-term patient outcomes in aortic stenosis. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The deal gives Regeneron access to Helicon peptide technology as pharma companies race to unlock previously “undruggable” intracellular targets. Regeneron Expands Intracellular Drug Platform Strategy with $2.32bn Parabilis Collaboration The deal gives Regeneron access to Helicon peptide technology as pharma companies race to unlock previously “undruggable” intracellular targets. Regeneron Pharmaceuticals has signed a research collaboration worth up to $2.32bn with Parabilis Medicines, securing access to the company’s Helicon peptide platform to develop antibody-Helicon conjugates (AHCs) and next-generation intracellular therapies. The partnership strengthens Regeneron’s push into precision biologics and targeted intracellular delivery, combining Parabilis’ stabilised peptide technology with Regeneron’s antibody engineering capabilities to potentially create an entirely new therapeutic class across multiple disease areas. A Strategic Move Beyond Traditional Antibody Therapies At the centre of the collaboration is Parabilis’ Helicon platform, which uses stabilised, cell-penetrant alpha-helical peptides engineered to interact with intracellular protein targets that are difficult or impossible to address with conventional small molecules or antibodies. The companies plan to explore Helicons both as standalone therapeutics and as payloads within antibody-Helicon conjugates, allowing Regeneron’s antibodies to selectively deliver intracellularly active peptides directly to target cells. This approach is designed to extend biologic drug development beyond extracellular targets and into intracellular disease pathways traditionally considered inaccessible to antibody-based medicines. Building a New Therapeutic Modality Regeneron believes the combination of VelocImmune-derived antibodies with intracellular Helicon payloads could establish a new platform capable of spanning oncology, immunology, and other therapeutic categories. Under the agreement, Parabilis will receive $125m upfront through a combination of cash and equity investment, alongside eligibility for up to $2.2bn in milestone payments and tiered royalties tied to future development and commercial success. The partnership also allows for expansion into additional targets through future option payments, while Regeneron will lead development, manufacturing, and global commercialisation activities. Why This Deal Matters Now The collaboration reflects a growing pharmaceutical focus on intracellular targeting technologies as companies search for ways to access disease-driving proteins beyond the reach of traditional therapeutics. As competition intensifies in antibody-drug conjugates, radiopharmaceuticals, and precision biologics, companies are increasingly investing in platform technologies that can unlock differentiated mechanisms rather than pursuing single-asset strategies. Helicon peptides represent part of a broader industry effort to bridge the gap between biologics and small molecules by combining targeting precision with intracellular activity. What This Means for the Industry The Regeneron–Parabilis partnership highlights several major trends shaping biotech and pharmaceutical R&D: Platform-based partnerships are becoming central to pipeline expansion strategies Intracellular protein targeting is emerging as a major next-generation therapeutic frontier Antibody conjugate technologies are expanding beyond traditional cytotoxic payloads Pharma companies are increasingly investing in modality innovation rather than single-product acquisitions The deal also reinforces Regeneron’s broader strategy of building diversified therapeutic platforms across biologics, radiopharmaceuticals, and advanced delivery technologies. Summary Regeneron’s $2.32bn collaboration with Parabilis Medicines signals growing industry momentum behind intracellular targeting platforms and next-generation biologic delivery systems. As pharma companies compete to access previously unreachable disease pathways, technologies that combine selective antibody delivery with intracellular activity are increasingly positioned as a new frontier in therapeutic development. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The funding round positions Decart at the centre of the race to build AI systems capable of understanding and interacting with the physical world in real time. AI infrastructure company Decart has secured $300m in a new funding round led by Radical Ventures, pushing total funding beyond $450m as competition intensifies around low-latency AI systems, world models, and physical AI infrastructure. The round attracted backing from major technology and venture investors including Amazon, Nvidia, Sequoia Capital, Adobe Ventures, Toyota Ventures, and Benchmark, reinforcing growing investor focus on the infrastructure layer powering next-generation AI applications beyond large language models. Building the Infrastructure Layer for Physical AI At the centre of Decart’s platform is its Decart Optimization Stack (DOS), an infrastructure system designed to improve AI inference and training efficiency while reducing compute costs across major hardware ecosystems including Nvidia GPUs, Google TPUs, and Amazon Trainium chips. Alongside DOS, the company is developing two real-time world models: Lucy, focused on immersive and interactive digital experiences such as gaming, streaming, commerce, and advertising Oasis, designed for physical AI applications including robotics and autonomous systems Decart argues that world models represent the next major evolution in AI, enabling systems to simulate environments, understand physics, and interact with continuously changing real-world conditions rather than operating purely through text-based reasoning. Why This Funding Round Matters Now The investment reflects a broader shift across the AI sector away from standalone language models and toward infrastructure capable of supporting persistent, real-time, environment-aware systems. As AI companies compete to move into robotics, autonomous systems, live simulation, and immersive digital experiences, demand is increasing for platforms that can process complex physical environments with low latency and high compute efficiency. Decart’s positioning is particularly notable because it sits across both infrastructure and application layers, allowing the company to monetise optimisation software while simultaneously developing proprietary world models. The company’s partnership with Amazon Web Services also signals growing hyperscaler interest in AI systems optimised for proprietary chip ecosystems such as Trainium. A Strategic Bet on World Models and Real-Time Simulation Decart has already integrated its technology with AWS Trainium hardware, enabling real-time world models to operate at scale inside existing enterprise infrastructure. The company says Lucy currently powers applications across virtual try-on, in-video advertising, gaming, streaming, and social media with sub-30ms response times, while Oasis is being developed for robotics and simulation-heavy environments requiring continuous spatial understanding. With DOS 2.0 now launched and updated versions of Lucy and Oasis scheduled for release, Decart is positioning itself as a foundational infrastructure provider for the next phase of AI deployment. What This Means for the Industry The Decart funding round highlights several major trends reshaping the AI market: AI investment is shifting toward infrastructure and optimisation layers rather than standalone foundation models World models are emerging as a key battleground in robotics, simulation, and immersive computing Cloud providers are increasingly partnering with AI infrastructure companies to drive adoption of proprietary chips Real-time, low-latency AI systems are becoming critical for physical AI and interactive consumer applications The deal also reinforces the growing convergence between AI infrastructure, gaming, robotics, cloud computing, and immersive digital experiences. Summary Decart’s $300m funding round signals growing investor confidence in world models and real-time AI infrastructure as the industry moves beyond text generation and into physical environment simulation. As competition intensifies around robotics, autonomous systems, and immersive AI applications, infrastructure platforms capable of delivering low-latency, environment-aware intelligence are increasingly becoming one of the most strategically valuable layers in the AI stack. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The combination forms one of the largest dedicated healthcare investors globally, spanning pharma, medtech, diagnostics, and healthcare infrastructure across three continents. GHO Capital and CBC Group have agreed to merge their operations to form a combined healthcare investment platform with more than $21bn in assets under management, creating what the firms describe as the world’s largest healthcare-focused investment organisation. The new entity brings together over 200 employees across 13 global offices and will invest across pharmaceuticals, medical devices, life sciences tools, diagnostics, healthcare infrastructure, and healthcare IT, reflecting a full-stack approach to healthcare innovation and capital deployment. A Global Platform for Healthcare Capital Deployment The combined firm is designed to connect healthcare innovation ecosystems across North America, Europe, and Asia-Pacific, regions that together account for approximately 90% of global healthcare R&D spending. By integrating investment capabilities across geographies, the platform aims to accelerate international scaling for portfolio companies while improving access to growth-stage healthcare innovation in both developed and emerging markets. Leadership at CBC Group has highlighted the goal of linking leading healthcare companies with global pools of capital to improve efficiency in addressing unmet medical needs and expanding access to care. Expanding Scale Across Healthcare Investment Themes GHO Capital closed its most recent Fund IV at over €2.5bn, bringing total assets under management to approximately €9bn, while CBC Group manages around $10.8bn following the close of its R-Bridge Healthcare Fund II. Both firms have built diversified portfolios spanning biotech, healthcare services, diagnostics, and digital health. Recent investments include contract development and manufacturing organisations, AI-driven R&D platforms, molecular diagnostics companies, and specialty pharmaceutical assets across global markets. This combined portfolio breadth reflects a growing trend in healthcare investing toward platform diversification across both physical and digital healthcare infrastructure. Why This Merger Matters Now The formation of a $21bn healthcare investment platform signals continued consolidation in healthcare private capital, particularly as investors seek scale advantages in a fragmented global innovation landscape. With healthcare R&D increasingly globalised and data-driven, investment firms are expanding beyond traditional regional strategies to build cross-border platforms capable of deploying capital across multiple healthcare subsectors simultaneously. The merger also reflects rising interest in AI-enabled healthcare, precision medicine, and infrastructure-level investments that support drug development, diagnostics, and clinical deployment at scale. What This Means for the Industry The GHO–CBC combination highlights several structural shifts in healthcare investment: Healthcare private equity and growth capital are consolidating into global mega-platforms> Cross-border capital deployment is becoming essential in capturing healthcare innovation cycles Investment strategies are increasingly focused on integrated healthcare ecosystems rather than single subsectors. As healthcare innovation becomes more interconnected across geographies and technologies, scale is emerging as a key differentiator in accessing and commercialising next-generation therapies and platforms. Summary The merger of GHO Capital and CBC Group to form a $21bn healthcare investment firm represents a major consolidation in global healthcare investing, bringing together capital, expertise, and international reach across pharma, medtech, and healthcare technology. The combined platform reflects a broader shift toward globalised, technology-enabled healthcare investment strategies designed to accelerate innovation and scale across the entire healthcare value chain. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The move comes just days after a multi-billion dollar partnership with Regeneron, signalling strong investor appetite for next-generation intracellular targeting platforms. The move comes just days after a multi-billion dollar partnership with Regeneron, signalling strong investor appetite for next-generation intracellular targeting platforms. Parabilis Medicines has filed to go public, seeking to raise capital to advance its lead oncology candidate zolucatetide into Phase III development for desmoid tumours, while expanding its broader pipeline of Helicon-based therapeutics across multiple cancer indications. The IPO filing follows a recent collaboration with Regeneron Pharmaceuticals worth up to $2.2bn in milestones, reinforcing growing industry interest in peptide-based platforms designed to target previously “undruggable” intracellular protein interactions. A Next-Generation Oncology Mechanism Targeting Wnt/β-Catenin Signalling At the centre of Parabilis’ pipeline is zolucatetide, an intravenous therapy built on the company’s Helicon platform. The drug is designed to inhibit the interaction between β-catenin and T-cell factor (TCF) transcription factors, a key signalling axis implicated in Wnt-driven cancers including desmoid tumours, colorectal cancer, and hepatocellular carcinoma. Zolucatetide is currently in Phase I/II development for desmoid tumours, with Phase III initiation planned for the first half of 2027, subject to continued clinical progress and financing from the public offering. Beyond its lead programme, Parabilis is also advancing additional indications in familial adenomatous polyposis, hepatocellular carcinoma, and colorectal cancer, alongside early-stage programmes including ERG and androgen receptor degraders. Capitalising on Momentum from Regeneron Partnership The IPO comes shortly after Parabilis secured a major collaboration with Regeneron Pharmaceuticals, which includes $50m upfront, a $75m equity investment commitment, and up to $2.2bn in potential milestone payments tied to Helicon and antibody-Helicon conjugate development. This partnership validates growing industry interest in Helicon peptides as a platform for intracellular targeting and reinforces Parabilis’ positioning as a key emerging player in next-generation oncology modalities. The company previously raised $305m in a Series F round earlier this year, highlighting sustained investor confidence ahead of its public market debut. A Busy IPO Window for Biotech If successful, Parabilis would become the twelfth biotech IPO of the year, continuing a resurgence in life sciences public listings following a period of capital market slowdown. Recent notable offerings include Kailera Therapeutics’ $625m IPO, alongside public debuts from Odyssey Therapeutics, Hemab Therapeutics, Seaport Therapeutics, and Avalyn Pharma, reflecting renewed investor appetite for clinical-stage innovation with platform potential. This trend suggests a selective reopening of biotech capital markets, with investors favouring companies that combine strong platform technologies with near-term clinical catalysts. Why This IPO Matters Now Parabilis sits at the intersection of three accelerating biotech trends: Platform-based drug discovery targeting intracellular biology Increased investor appetite for clinical-stage oncology assets with defined mechanisms Capital market reopening for differentiated biotech IPOs with clear Phase II/III transition pathways The company’s focus on Wnt/β-catenin signalling also places it in one of oncology’s most challenging but biologically validated pathways, long considered difficult to drug effectively. What This Means for the Industry The Parabilis IPO highlights several key shifts in biotech financing and innovation: Platform biotech companies are increasingly leveraging IPOs to fund late-stage clinical expansion Intracellular and transcription factor targeting remains a high-value frontier in oncology Public markets are selectively reopening for companies with validated mechanisms and clear clinical catalysts Strategic pharma partnerships are becoming critical de-risking signals ahead of IPO execution Together, these dynamics point to a biotech funding environment increasingly shaped by platform credibility, mechanistic differentiation, and near-term clinical visibility. Summary Parabilis Medicines’ IPO filing marks a pivotal step in funding the expansion of its Helicon-based oncology pipeline, anchored by zolucatetide in desmoid tumours and broader Wnt-driven cancer indications. Coming shortly after a major Regeneron partnership, the move underscores rising investor confidence in intracellular targeting platforms and signals continued momentum in biotech public markets for differentiated, mechanism-led companies. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure. Jardine Matheson has agreed to acquire Australian diagnostic imaging provider I-MED Radiology Network for an enterprise value of A$3.4bn ($2.4bn), securing one of the largest radiology and teleradiology platforms in the Asia-Pacific region. The deal includes I-MED’s minority stake in Harrison.ai, an artificial intelligence company developing radiology tools for CT brain and chest imaging, adding an AI component to an already significant healthcare infrastructure acquisition. A Strategic Bet on Diagnostic Infrastructure I-MED operates 215 clinics across Australia and New Zealand and performs more than seven million patient procedures annually through a network of over 500 radiologists. Its services span MRI, CT, PET, nuclear medicine, ultrasound, and X-ray imaging, providing coverage across both metropolitan and regional healthcare markets. Alongside its physical clinic footprint, I-MED has built a substantial teleradiology operation, delivering remote image interpretation services across Australia, New Zealand, and the United States. This combination of physical infrastructure, specialist workforce, and digital reporting capability makes I-MED one of the most comprehensive imaging platforms in the region. Why Harrison.ai Matters While the acquisition is primarily focused on I-MED’s diagnostic imaging operations, the inclusion of its stake in Harrison.ai is strategically significant. Harrison.ai develops artificial intelligence solutions designed to support radiologists in interpreting medical imaging, including CT brain and chest scans. As imaging volumes continue to rise globally and radiologist shortages persist across multiple healthcare systems, AI-assisted diagnostics are increasingly viewed as a critical productivity and workflow enhancement tool. The transaction therefore provides Jardine Matheson with exposure not only to diagnostic imaging demand but also to one of healthcare’s fastest-growing technology categories. Why This Deal Matters Now The acquisition reflects growing investor interest in healthcare infrastructure assets that sit at the intersection of service delivery, clinical data generation, and artificial intelligence. Diagnostic imaging occupies a particularly valuable position within healthcare because it combines: Recurring patient demand Large-scale clinical data generation Increasing AI integration opportunities Essential diagnostic workflows As healthcare systems seek to improve efficiency and address workforce shortages, imaging networks are becoming increasingly attractive strategic assets. The inclusion of Harrison.ai further reinforces the growing convergence between healthcare services and AI-enabled clinical decision support. What This Means for the Industry The Jardine Matheson-I-MED transaction highlights several major trends shaping healthcare investment: Diagnostic imaging is emerging as a high-value healthcare infrastructure asset class AI is increasingly becoming embedded within clinical workflows rather than existing as a standalone technology category Investors are targeting businesses that combine service delivery with proprietary healthcare data generation Teleradiology continues to expand as healthcare systems seek greater workforce flexibility and coverage The deal also demonstrates how healthcare investors are increasingly seeking assets that provide both operational scale today and technology-driven growth opportunities tomorrow. Summary Jardine Matheson’s $2.4bn acquisition of I-MED Radiology Network represents a major investment in healthcare infrastructure, combining one of Australasia’s largest diagnostic imaging providers with exposure to emerging AI-powered radiology technologies. As healthcare increasingly converges with data, diagnostics, and artificial intelligence, platforms capable of generating, interpreting, and scaling clinical insight are becoming some of the most strategically valuable assets in the sector. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance. Eli Lilly has announced agreements to acquire three companies, Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, in a coordinated move to build a broader infectious disease and vaccine prevention portfolio spanning viral and bacterial pathogens. The strategy reflects a growing industry shift from treating infectious diseases after onset to preventing downstream chronic conditions linked to infection, including neurological disease, cancer, and reproductive health complications. A Strategic Shift Toward Prevention-Based Medicine Across all three acquisitions, Lilly is positioning infectious disease prevention as a long-term intervention against both acute infection and its downstream health consequences. The company highlighted growing scientific evidence linking common infections to conditions that emerge years later, alongside increasing concerns over antimicrobial resistance that is limiting the effectiveness of traditional antibiotic therapies. By integrating vaccine platforms across viral and bacterial pathogens, Lilly is expanding its R&D footprint into prevention-first medicine as a structural growth area within biopharma. Curevo Brings Next-Generation Shingles Vaccine Candidate Curevo’s lead asset, amezosvatein, is a recombinant subunit vaccine for the prevention of shingles in adults, designed with a next-generation synthetic adjuvant to improve tolerability while maintaining strong immune response. In Phase 2 head-to-head data versus the current standard of care, the vaccine demonstrated comparable immune responses while significantly reducing side effects such as fatigue, chills, and injection site pain. This improved tolerability profile could be important in increasing vaccination uptake, particularly in older populations where shingles is associated with elevated risk of complications including stroke and potential links to cognitive decline. Under the agreement, Curevo shareholders could receive up to $1.5bn in cash, including upfront and milestone-based payments. LimmaTech Advances Bacterial Vaccine Platform Amid Antibiotic Resistance LimmaTech Biologics is developing vaccines targeting high-burden bacterial pathogens including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis, areas where antimicrobial resistance is rapidly reducing treatment options. Its platform is designed to generate broad immune responses by targeting bacterial toxins and disease-driving antigens, with its lead candidate LTB-SA7 currently in Phase 1 development for prevention of S. aureus infections, a leading cause of surgical-site complications. The broader pipeline targets infections associated with long-term health outcomes such as infertility and chronic disease, particularly in underserved populations. Lilly will acquire LimmaTech for up to $780m, including upfront and milestone-based payments. Vaccine Company Targets Viral-Linked Chronic Disease Risk Vaccine Company is developing an In Vivo Nanoparticle (IVN) platform designed to replicate virus-like particle immune responses while simplifying manufacturing compared to traditional VLP vaccines. Its lead programme targets Epstein-Barr Virus (EBV), a pathogen increasingly associated with long-term neurological and oncological conditions, including multiple sclerosis and certain cancers. The approach aims to prevent both acute infection and potential downstream disease burden through early immune intervention. The acquisition is valued at up to $1.55bn in cash, including upfront and milestone-linked payments. Why This Deal Matters Now Lilly’s three-acquisition strategy reflects a broader pharmaceutical pivot toward: Prevention of long-term disease rather than treatment of acute infection Vaccine innovation as a response to antimicrobial resistance Recognition of infection-linked chronic disease pathways Platform-based vaccine development across multiple pathogen classes This positions infectious disease not just as an acute care area, but as a foundational lever in reducing lifetime disease burden across neurological, oncological, and reproductive health outcomes. What This Means for the Industry The transactions highlight several structural shifts in pharma strategy: Vaccine platforms are becoming core strategic assets for large pharma companies Infectious disease is increasingly linked to chronic disease prevention narratives Antimicrobial resistance is accelerating investment in non-antibiotic solutions Multi-asset acquisitions are replacing single-program deals in prevention-focused R&D Lilly’s approach signals a long-term bet that prevention-based medicine will become one of the largest growth areas in global healthcare. Summary Eli Lilly’s acquisition of Curevo, LimmaTech Biologics, and Vaccine Company marks a coordinated expansion into infectious disease prevention, positioning vaccines as tools not only against infection but also against long-term neurological and oncological risk. The strategy reflects a broader shift in pharmaceutical R&D toward platform-based prevention technologies designed to address both acute disease and its downstream chronic consequences. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Eli Lilly and Ascidian Therapeutics have entered into a multi-year strategic collaboration worth up to $1.9bn, focused on developing RNA exon-editing therapies for undisclosed monogenic kidney diseases. The deal reflects a broader industry shift toward platform-based genetic medicine partnerships, where large pharma increasingly secures access to modular, early-stage technologies rather than individual assets, in order to expand therapeutic reach across high-unmet-need disease areas. A Platform Deal Built Around RNA Exon Editing The collaboration centres on RNA exon editing, a post-transcriptional gene modulation approach designed to precisely modify RNA sequences without altering underlying DNA. Developed by Ascidian Therapeutics, the platform aims to: Enable highly targeted correction of disease-causing genetic errors Support potential one-time or durable therapeutic interventions Expand treatable space in monogenic and genetically defined diseases The approach is being explored across multiple therapeutic areas, including renal, neurological, retinal, and neuromuscular disorders, with this agreement initially focused on kidney disease targets. A Structured Division of Development Responsibilities Under the terms of the collaboration: Ascidian Therapeutics will: Lead target discovery Conduct selected preclinical development activities Drive early platform advancement and programme selection Eli Lilly and Company will: Hold exclusive, target-specific rights in kidney disease Lead additional preclinical development Oversee clinical development Manage manufacturing and global commercialisation This structure reflects a clear separation of innovation generation (biotech) and late-stage execution (pharma), designed to accelerate translation while managing development risk. Financial Structure and Incentive Design: The agreement includes: An undisclosed upfront payment to Ascidian Up to $1.9bn in total potential deal value, including milestones Additional tiered royalties on future product sales Milestone payments are expected to be tied to: Clinical development progress Regulatory approvals Commercial performance thresholds The structure aligns long-term incentives across both parties while maintaining flexibility for programme expansion into additional targets. Why This Deal Matters Now The Lilly–Ascidian collaboration reflects several accelerating trends in genetic medicine and pharma strategy: Platform over asset thinking. Pharma companies are increasingly investing in technologies that can generate multiple therapeutic candidates rather than single-indication drugs. RNA-based modalities are gaining traction. RNA exon editing adds to a growing toolkit of genetic medicine approaches, alongside gene editing, RNA interference, and antisense technologies. Expansion into hard-to-treat monogenic disease. Kidney disease represents a high-value, high-unmet-need area where traditional small molecules and biologics have had limited impact. Earlier-stage risk transfer models. Large pharma continues to move upstream into discovery-stage collaborations, absorbing later-stage risk in exchange for earlier access to innovation. Strategic Implications for the Industry This agreement reinforces a structural shift in how genetic medicines are being developed: Early-stage biotech platforms are becoming multi-program revenue engines rather than single-asset stories Large pharma is increasingly acting as a late-stage development and commercialisation layer for external innovation RNA-based therapeutic classes are moving from experimental to strategically investable platforms Monogenic disease areas are becoming key entry points for next-generation genetic technologies For Lilly, the deal strengthens its position in advanced genetic and precision medicine modalities. For Ascidian, it provides both validation and capital efficiency to scale a relatively young platform technology. What to Watch Next Key developments to monitor include: Identification of specific kidney disease targets under the agreement Preclinical validation of RNA exon editing durability and specificity Safety and off-target profiling in translational models Timeline to first-in-human studies Potential expansion of the platform into additional therapeutic areas within the Lilly partnership Summary The $1.9bn Lilly–Ascidian collaboration represents a strategic expansion of RNA exon editing into monogenic kidney disease, combining platform-based biotech innovation with large pharma development and commercial infrastructure. More broadly, it reflects a continued shift in global pharmaceutical R&D toward multi-program, platform-driven partnerships designed to scale genetic medicine across multiple disease areas while distributing risk across the development lifecycle. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The partnership expands a global co-development model spanning ADCs, multispecific antibodies, and early-stage oncology assets across US and China markets. Pfizer and Innovent Biologics have entered a multi-program oncology collaboration worth up to $10bn+, covering 12 cancer therapeutics and combining early-stage discovery, clinical development, and global commercialisation across a shared pipeline. The deal reflects an increasingly common pharma strategy: accessing external innovation at scale through structured partnerships that split risk, geography, and development responsibility while accelerating access to differentiated oncology mechanisms. A 12-Asset Oncology Pipeline Spanning Two Innovation Engines The collaboration includes eight early-stage assets originating from Innovent and four discovery programmes proposed by Pfizer, spanning antibody-drug conjugates (ADCs) with novel payloads and multispecific antibodies designed to enhance immune engagement. Under the agreement, Innovent will lead discovery and Phase I development, after which Pfizer will take over global development responsibilities for selected programmes. The structure enables Pfizer to access a broad early-stage pipeline while leveraging Innovent’s established oncology discovery capabilities and clinical development infrastructure. A Multi-Layered Global Development Model The financial structure includes a $650m upfront payment to Innovent, with eligibility for up to $9.85bn in milestone payments tied to development, regulatory approvals, and commercial performance. The collaboration is split across three operational models: Four programmes licensed exclusively to Pfizer globally, with Pfizer assuming full development and commercial responsibility Four programmes licensed to Pfizer ex-China, with Pfizer leading global development outside Greater China Four programmes co-developed globally, with shared development costs and profit-sharing arrangements across the US, EU, UK, and China This hybrid structure reflects a more sophisticated approach to global drug development, balancing local innovation ecosystems with multinational commercial execution. Why This Deal Matters Now The Pfizer–Innovent partnership highlights several key trends in global oncology R&D: Pharma companies are increasingly relying on structured multi-asset collaborations rather than single-asset licensing deals. China-based biotech firms are becoming central nodes in global early-stage oncology innovation ADCs and multispecific antibodies remain among the most competitive and capital-intensive therapeutic classes. Risk-sharing models are becoming standard in large-scale oncology pipelines. The deal also underscores the growing importance of China as both a source of early-stage innovation and a strategic development partner for global pharmaceutical companies. What This Means for the Industry This collaboration reflects a broader structural shift in pharma strategy: Pipeline access is replacing asset acquisition as the dominant growth model Development responsibility is increasingly segmented by geography and stage Multinational co-development structures are becoming standard in oncology Early-stage biotech innovation is increasingly globalised across US–China partnerships Pfizer’s involvement signals continued prioritisation of oncology expansion through external innovation rather than purely internal discovery. Summary The $10bn+ Pfizer–Innovent collaboration represents a major expansion in global oncology co-development, spanning 12 programmes across ADC and multispecific antibody platforms. The deal reflects a broader shift toward multi-asset, risk-sharing partnerships designed to accelerate early-stage innovation while distributing development and commercial responsibilities across global markets. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The approval introduces the first immunotherapy combination for BCG-naïve high-risk non-muscle-invasive bladder cancer, marking a potential shift in the standard of care. The FDA has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) for adults with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), becoming the first immunotherapy-based combination approved in this setting. The decision was supported by Phase III POTOMAC trial data showing a 32% reduction in the risk of disease recurrence, progression, or death compared with BCG alone. With more than five years of follow-up, the Imfinzi regimen delivered sustained disease-free survival benefits while maintaining a safety profile consistent with the individual therapies, reinforcing its potential to establish a new treatment benchmark for high-risk NMIBC patients. Alert Type Regulatory Approval (FDA) Drug/Device Name Imfinzi (durvalumab) + Bacillus Calmette-Guérin (BCG) Indication BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) in adults Therapy Area(s) Oncology, Urology, Bladder Cancer, Immuno-oncology Geography United States (FDA approval) What Changed The FDA approved AstraZeneca’s Imfinzi (durvalumab) in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC. Based on the Phase III POTOMAC trial, the combination reduced the risk of high-risk disease recurrence, progression, or death by 32% compared with BCG alone, becoming the first approved immunotherapy combination in this setting. Clinical Relevance The approval introduces a new treatment paradigm for high-risk NMIBC by adding immunotherapy to the long-established BCG backbone. The regimen demonstrated durable disease-free survival benefits over more than five years of follow-up while maintaining a manageable safety profile, preserving BCG treatment completion rates, and not negatively affecting patient-reported quality of life. Source Link https://www.globaldata.com/newsletter/details/fda-approves-astrazeneca-s-imfinzi-bcg-combination-for-nmibc-therapy_383859/ Date 1-Jun-2026 Status Draft Notes POTOMAC Phase III data showed a disease-free survival hazard ratio of 0.68 with a median follow-up of 60.7 months. No new safety signals were identified versus the known profiles of Imfinzi and BCG. Regulatory reviews are ongoing in the EU, Japan, and other markets. The approval further expands Imfinzi’s role across the bladder cancer treatment pathway alongside ongoing Phase III programmes including VOLGA, NIAGARA, and NILE. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Daraxonrasib, KRAS G12D, and the ASCO26 Signal That Broke a Long Silence At ASCO26, there are always moments the field remembers. Some are technical milestones. Some are survival curves. And occasionally, there is something more difficult to quantify — a collective reaction that tells you the data has crossed from analysis into belief. The presentation of new results in metastatic pancreatic cancer involving daraxonrasib appeared to land in that category. Reports from the room describe standing ovations, not as theatre, but as release — after years of incremental progress in a disease that has resisted almost every meaningful therapeutic advance. This article breaks down what was presented, why it matters, and how the wider oncology ecosystem is interpreting it. The Disease That Has Defined “Unmet Need” for Decades Pancreatic cancer remains one of the most challenging solid tumours in oncology. Despite advances across other cancer types, PDAC has been defined by: Late-stage diagnosis in most patients Rapid clinical deterioration Limited response durability to chemotherapy Few actionable molecular targets with proven clinical impact For years, the phrase “modest improvement” has been the dominant language of pancreatic cancer progress. ASCO26, at least in this dataset of reactions and commentary, is being framed differently. KRAS G12D: The Target That Defined the Limits of Oncology A key scientific anchor in this story is KRAS G12D, a mutation present in a substantial proportion of pancreatic cancers. Biologically, KRAS sits upstream in a signalling cascade that drives: Cell proliferation Survival signalling Metabolic adaptation Tumour persistence under therapeutic pressure For decades, KRAS was labelled “undruggable” — not because it was unimportant, but because it was structurally difficult to inhibit in a clinically meaningful way. That framing has been slowly eroded over recent years. What ASCO26 adds, according to multiple reports, is a more concrete step: evidence of clinically meaningful impact in a large, difficult-to-treat population. What the Data Is Showing Across commentary and referenced subgroup data, several consistent signals emerge: In previously treated KRAS-mutant populations, response rates around ~35% have been reported in early analyses Median duration of response cited at approximately 8 months in some subgroups Overall survival benefit described by attendees and commentators as clinically significant versus chemotherapy, with some describing it as approaching a doubling effect (final peer-reviewed confirmation pending) The key distinction here is not just response, but durability in a disease where durability has historically been rare. Importantly, these results are being associated with the investigational agent daraxonrasib, suggesting a broader shift in how KRAS-driven biology may now be therapeutically addressed. Why This Moment Feels Different What stands out in the ASCO26 reaction data is not only what was presented, but how it was received. Across clinicians, researchers, industry leaders, and patient advocates, a few phrases repeat: “historic” “breakthrough” “goosebumps” “long overdue” “standing ovation moment” This matters because oncology conferences typically reward restraint. Emotional convergence at scale usually signals that something has shifted from incremental to directional. In other words, the reaction itself becomes a secondary dataset. The Patient Layer: Why the Science Landed Emotionally One of the most striking aspects of the discourse is how frequently patients and families are present in the narrative — not abstractly, but directly. Several themes appear repeatedly: Patients who participated in early trials now represented in later success narratives Families linking scientific progress to personal loss or survival Hope framed not as abstract optimism, but as additional time: months, milestones, memories In pancreatic cancer specifically, where prognosis has often been measured in short timeframes, even incremental gains carry disproportionate emotional weight. That is part of why the reaction was not purely scientific. Where This Leaves the Field If these findings hold through full peer-reviewed publication and regulatory validation, the implications are significant: 1. KRAS is no longer a theoretical target class It is becoming a clinically actionable pathway in PDAC. 2. Pancreatic cancer treatment may be entering a stratified era Biomarker-driven therapy (including KRAS subtyping) moves from research concept to practical decision layer. 3. Competitive oncology pipelines will accelerate Success in KRAS G12D inevitably increases pressure across: RAS pathway programmes Combination immunotherapy strategies Earlier-line intervention studies What Still Needs to Be Proven Despite the strength of the signal, several questions remain open: How durable are the survival benefits at full population scale? How does toxicity compare to standard chemotherapy over time? Will efficacy extend across broader KRAS-driven tumour types? Can this be moved earlier in treatment lines with maintained benefit? These are not minor details — they determine whether this becomes a practice-changing therapy or a high-impact niche advance. A Measured Interpretation of a High-Emotion Moment ASCO26, in this dataset, is being described as a turning point. Whether it ultimately becomes one will depend on what emerges in full publication, regulatory review, and real-world use. But the current signal is clear enough to justify attention: For a disease long defined by stagnation, any consistent, meaningful survival signal in KRAS G12D pancreatic cancer is structurally important. And that is why the reaction in the room — scientific, emotional, and collective — is itself part of the story. Not because emotion replaces evidence. But because sometimes, it reflects the moment evidence begins to feel like change. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Alnylam Pharmaceuticals has entered a collaboration worth up to $2bn with Inceptive Nucleics, combining RNA interference (RNAi) drug development expertise with generative AI models specifically designed for sequence-based medicines. The partnership reflects a growing shift across biopharma: moving AI beyond administrative efficiencies and into the core scientific process of therapeutic design, where machine learning is increasingly being used to identify, optimise, and prioritise drug candidates before they reach the laboratory. Bringing Generative AI Into RNA Medicine Design Under the agreement, Alnylam will pay Inceptive $30m upfront through a combination of cash and equity investment, while the AI company becomes eligible for additional preclinical, regulatory, and commercial milestone payments that could bring the total deal value to approximately $2bn. The collaboration centres on Inceptive’s foundation models, which have been trained specifically on biological sequence data and are designed to generate insights across RNA-based therapeutic platforms. Unlike many AI systems that require extensive retraining for new applications, Inceptive’s models are designed to learn biological patterns directly from sequence data and adapt across different therapeutic modalities. The companies believe this capability could significantly reduce the time required to identify and optimise new RNAi candidates. Optimising siRNA Development at Scale The focus of the collaboration is the development of small interfering RNA (siRNA) therapeutics, a modality that forms the foundation of Alnylam’s commercial portfolio. Together, the companies aim to: Model target messenger RNA (mRNA) structures and behaviours Explore large sequence spaces to identify promising siRNA candidates Evaluate chemical modifications that could improve potency and durability Predict therapeutic performance before laboratory testing Prioritise the most promising molecules for further development The objective is not simply to generate more candidates, but to improve candidate quality earlier in the development process, reducing costly experimental cycles and increasing the probability of success. Why AI Is Becoming Central to Drug Discovery Drug discovery increasingly involves navigating enormous biological search spaces that are difficult to explore using conventional experimental methods alone. The challenge is particularly acute in RNA medicine, where therapeutic performance can be influenced by complex interactions between sequence design, target biology, delivery mechanisms, and chemical modifications. AI systems are increasingly being positioned as a solution to this complexity. Rather than relying solely on iterative laboratory testing, companies are using foundation models to predict which molecular designs are most likely to succeed before significant resources are committed. This approach has the potential to shorten development timelines, improve productivity, and reduce the cost of early-stage R&D. A Significant Milestone for Inceptive The agreement represents Inceptive’s first publicly disclosed biopharmaceutical partnership since the company emerged from stealth and raised $100m in financing. The company was founded by Jakob Uszkoreit, a former Google AI researcher who helped develop the Transformer architecture, the breakthrough innovation that underpins modern large language models including ChatGPT. Inceptive’s core thesis is that biological systems contain patterns of complexity that can be learned and modelled through large-scale AI systems in much the same way language models learn linguistic structures. The Alnylam partnership provides one of the clearest commercial validations of that approach to date. What This Means for the Industry The collaboration highlights several broader trends reshaping pharmaceutical R&D: AI is moving from workflow automation into core scientific decision-making Foundation models are increasingly being trained specifically for biological applications RNA therapeutics remain a major area of investment following the commercial success of RNA-based medicines Pharma companies are seeking AI partnerships that directly impact pipeline productivity Early-stage drug design is becoming increasingly computational before laboratory validation The deal also reflects growing confidence that AI can contribute tangible value not just in identifying drug targets, but in designing the therapeutic molecules themselves. Summary The $2bn Alnylam–Inceptive partnership represents one of the most significant recent examples of AI being integrated directly into therapeutic discovery. By combining Alnylam’s RNAi expertise with Inceptive’s sequence-focused foundation models, the companies aim to accelerate the design and optimisation of siRNA medicines while reducing the time and cost associated with traditional discovery processes. More broadly, the deal signals a shift in pharmaceutical R&D where AI is increasingly becoming a core component of how new medicines are designed, selected, and advanced into development. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com